ArticleFrontiers in cardiovascular medicine2026
The prognostic value of triglyceride glucose-waist height ratio index in patients with heart failure after acute myocardial infarction: a retrospective study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) after acute myocardial infarction (AMI) remains a major clinical challenge. The triglyceride glucose-waist-to-height ratio (TyG-WHtR) integrates metabolic and obesity indices, yet its prognostic value for AMI-HF is unclear. Methods: This retrospective study enrolled 738 AMI patients undergoing PCI from January 2019 to June 2024. Baseline TyG-WHtR was calculated pre-discharge. The primary outcome was HF occurrence within 1-year follow-up. Multivariate logistic regression and restricted cubic splines (RCS) assessed associations. Receiver operating characteristic (ROC) curves and DeLong tests compared TyG-WHtR against the GRACE score and other metabolic indices. Subgroup analyses were performed based on AMI-to-PCI time and ESC-defined HF classifications. Results: A total of 136 patients (18.4%) developed HF. TyG-WHtR was an independent predictor of AMI-HF (adjusted OR = 1.192, 95% CI: 1.021∼1.392, Conclusion: TyG-WHtR is an independent risk factor for 1-year AMI-HF, particularly in HFpEF phenotypes. It provides incremental prognostic value beyond the GRACE score and may guide early risk stratification in post-PCI AMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.